A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 793-799

  Schwartz, Stanley S ^a,b  

^a Main Line Health Heart Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ada EASD position statement; Cardiovascular risk; Clinical management; Patient centered; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BROMOCRIPTINE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; AEROBIC EXERCISE; AGONIST; ANGINA PECTORIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES EDUCATION; DISEASE DURATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG TARGETING; EARLY INTERVENTION; EXERCISE; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KINESIOTHERAPY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT COUNSELING; RESISTANCE TRAINING; REVIEW; RISK REDUCTION; SELF CARE; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; LIVER DISEASES; MALE; PATIENT-CENTERED CARE;

EID: 84880299534     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.798637     Document Type: Review

References (41)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
3. Committee on Quality of Health Care in America: Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press, 2001
4. Onglyza (saxagliptin). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2011
5. Galvus (vildagliptin). Full Prescribing Information. Camberley, Surrey: Novartis Pharmaceuticals UK Limited, 2012
6. Januvia (sitagliptin). Full Prescribing Information. Whitehouse Station, NJ: Merck & Co. Inc., 2012
7. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50 253-65
8. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010;70:807-14
9. He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vilda-gliptin. Eur J Clin Pharmacol 2007;63:677-86
10. Victoza (liraglutide [rDNA origin]). Full Prescribing Information. Princeton, NJ: Novo Nordisk Inc., 2012
11. Tradjenta (linagliptin). Full Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2012
12. Byetta (exenatide). Full Prescribing Information. San Diego, CA: Amylin Pharmaceuticals Inc., 2011
13. Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardio-vascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8
14. Nagajothi N, Adigopula S, Balamuthusamy S, et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a metaanalysis of randomized, controlled trials. Am J Ther 2008;15:506-11
15. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011 Mar 16;10:22. doi: 10.1186/1475-2840-10-22
16. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5
17. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8
18. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94
19. White WB, Gorelick PB, Fleck P, et al. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials [abstract] Diabetes 2010;59:391
20. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7. Published online 2010 April 22. doi: 10.1186/1472-6823-10-7
21. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012;11:6 Published online 2012 January 16. doi: 10.1186/1475-2840-11-6
22. Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3. Published online 2012 January 10. doi: 10.1186/1475-2840-11- 3
23. American Diabetes Association. Standards of medical care in diabetes, 2012. Diabetes Care 2012;35(Suppl 1):S11-63
24. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
25. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364: 1104-15
26. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300-7
27. Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379: 2243-51
28. Sherwin RS, Anderson RM, Buse JB, et al. Prevention or delay of type 2 diabetes. Diabetes Care 2004;27(Suppl 1):S47-54
29. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008;31(Suppl 1): S61-78
30. Ceriello A. The emerging challenge in diabetes: The 'metabolic memory' Vascul Pharmacol 2012;57:133-8
31. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012;14:803-9
32. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidia-betes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
33. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9
34. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;267:319-28
35. Pories WJ, Dohm GL. Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence. Diabetes Care 2012;35:2438-22
36. Invokana (canagliflozin). Full Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals Inc., 2013
37. DeFronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789-94
38. Bays HE. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Endocr Pract 2011;17:933-8
39. Ranexa (ranolazine). Full Prescribing Information. Foster City, CA: Gilead Sciences Inc., 2011
40. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-9
41. Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68